Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Incyte (NASDAQ:INCY) gained $1.92 (20%) to $11.39 on Tuesday after reporting data
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury